Alembic Pharmaceuticals receives USFDA approval for Ketorolac Tromethamine Injection

3 Nov 2022 , 10:49 AM

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 15 mg/mL, 30 mg/mL, and 60 mg/2 mL (30 mg/mL) Single Dose Vials. This is the second injectable product approval from the companys General Sterile Facility (F-3) which was inspected in August, 2022Powered by Capital Market – Live News